Bespak’s first deal for its proprietary Syrina autoinjector platform is with an undisclosed major global biopharma. Syrina is based on proprietary VapourSoft technology that uses a liquid gas propellant (rather than a conventional spring) to provide the force for drug delivery. Bespak’s ability to customise its devices to the specifications of its biopharma customers provides a significant competitive edge, enabling delivery of higher volumes and a broader range of formulations (including viscous biologics) while reducing the risk of safety hazards for users. This first deal provides technology validation and may catalyse further injectables deals. Bespak has the potential to become the partner of choice in an environment where rising numbers of biologic drugs in development and increased pressure on healthcare costs make self-administration a more attractive option.
